Report

Global Treatment-resistant Depression Treatment Market Size study & Forecast, by Drug Type, by Distribution Channel and Regional Analysis, 2022-2029

  • Publish Date: Feb,2023
  • Report ID: 3-2-1663
  • Page : 200
  • Report Type : PDF (Email)
Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Treatment-resistant Depression Treatment Market, by Region, 2019-2029 (USD Billion)
1.2.2. Treatment-resistant Depression Treatment Market, by Drug Type, 2019-2029 (USD Billion)
1.2.3. Treatment-resistant Depression Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Treatment-resistant Depression Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Treatment-resistant Depression Treatment Market Dynamics
3.1. Treatment-resistant Depression Treatment Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rise in the prevalence of treatment-resistant depression
3.1.1.2. Increasing drug development projects
3.1.2. Market Challenges
3.1.2.1. Limited therapeutic measure
3.1.2.2. Lack of clarity in guidelines for diagnosis and management of this mood disorder patients
3.1.3. Market Opportunities
3.1.3.1. Rising investment in research and development activities
3.1.3.2. Increasing initiatives by the key market players
Chapter 4. Global Treatment-resistant Depression Treatment Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Treatment-resistant Depression Treatment Market, by Drug Type
6.1. Market Snapshot
6.2. Global Treatment-resistant Depression Treatment Market by Drug Type, Performance - Potential Analysis
6.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
6.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
6.4.1. NMDA
6.4.2. Antidepressants
6.4.3. Antipsychotics
6.4.4. Others
Chapter 7. Global Treatment-resistant Depression Treatment Market, by Distribution Channel
7.1. Market Snapshot
7.2. Global Treatment-resistant Depression Treatment Market by Distribution Channel, Performance - Potential Analysis
7.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
7.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
7.4.1. Hospital Pharmacies
7.4.2. Drug Stores & Retail Pharmacies
7.4.3. Online Pharmacies
Chapter 8. Global Treatment-resistant Depression Treatment Market, Regional Analysis
8.1. Treatment-resistant Depression Treatment Market, Regional Market Snapshot
8.2. North America Treatment-resistant Depression Treatment Market
8.2.1. U.S. Treatment-resistant Depression Treatment Market
8.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Treatment-resistant Depression Treatment Market
8.3. Europe Treatment-resistant Depression Treatment Market Snapshot
8.3.1. U.K. Treatment-resistant Depression Treatment Market
8.3.2. Germany Treatment-resistant Depression Treatment Market
8.3.3. France Treatment-resistant Depression Treatment Market
8.3.4. Spain Treatment-resistant Depression Treatment Market
8.3.5. Italy Treatment-resistant Depression Treatment Market
8.3.6. Rest of Europe Treatment-resistant Depression Treatment Market
8.4. Asia-Pacific Treatment-resistant Depression Treatment Market Snapshot
8.4.1. China Treatment-resistant Depression Treatment Market
8.4.2. India Treatment-resistant Depression Treatment Market
8.4.3. Japan Treatment-resistant Depression Treatment Market
8.4.4. Australia Treatment-resistant Depression Treatment Market
8.4.5. South Korea Treatment-resistant Depression Treatment Market
8.4.6. Rest of Asia Pacific Treatment-resistant Depression Treatment Market
8.5. Latin America Treatment-resistant Depression Treatment Market Snapshot
8.5.1. Brazil Treatment-resistant Depression Treatment Market
8.5.2. Mexico Treatment-resistant Depression Treatment Market
8.5.3. Rest of Latin America Treatment-resistant Depression Treatment Market
8.6. Rest of The World Treatment-resistant Depression Treatment Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Eli Lilly and Company
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. GlaxoSmithKline Plc
9.2.3. Pfizer Inc.
9.2.4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
9.2.5. AbbVie Inc.
9.2.6. AstraZeneca Plc
9.2.7. H. Lundbeck A/S
9.2.8. Sandoz International GmbH (Novartis AG)
9.2.9. Par Pharmaceutical (Endo International plc)
9.2.10. Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption